In multiple myeloma (MM) and leukemias, YAP appears to have a tumor-suppressive effect by controlling the Abl1-dependent DNA damage response, which causes programmed cell death in tumor cells. The gene discussed is ABL1; the disease is Miyoshi myopathy.